Analysis on Application of Anti-HBV Nucleoside ( acid ) Analogues Based on the Clinical Treatment of Hepatitis B in 302 Hospital of People' s Liberation Army During 2014-2016
Huan WANG,Jin XIE,Huifang HE,Liping LIU,Feifei YANG,Hongjuan NIU,Yanling ZHAO
DOI: https://doi.org/10.14009/j.issn.1672-2124.2017.09.006
2017-01-01
Abstract:OBJECTIVE:To investigate the application status and trend of anti-HBV nucleoside( acid) analogues based on the clinical treatment of hepatitis B in 302 Hospital of People' s Liberation Army, so as to provide reference for clinical rational drug application. METHODS: Retrospective analysis method was adopted, the consumption amount, comsumption sum, defined daily dose( DDDs) and defined daily cost( DDC) of anti-HBV nucleoside( acid) analogues based on the clinical treatment of hepatitis B extracted from in-patient pharmacy information system during 2014-2016 were statistically analyzed. RESULTS: The consumption amount and consumption sum of anti-HBV nucleoside( acid) analogues during 2014-2016 were in an increasing trend year to year, and the increasing rate was up to 11. 23％ in 2015 ( 3. 4299 million yuan in 2014 , 3. 6371 million yuan in 2015 ) . The consumption amount of entecavir and tenofovir was in an increasing trend, yet the clinical application of lamivudine, adefovir dipivoxil and telbivudine decreased year to year. For three years, the ratio of consumption sum ranking/medication frequence ranking was 1, which showed good synchronization between the number of patients and consumption sum. CONCLUSIONS:Nucleoside( acid) analogues has become the preferred drug for anti-HBV, the clinic are more likely to choose effective and low-resistance drugs as entecavir, adefovir dipivoxil and tenofovir in clinical treatment. The clinicians should regulate and rational application of anti-HBV nucleoside ( acid ) analogues, formulate rational treatment regimen according to the individual conditions and reduce the drug resistance.